Koers Vical Incorporated Nasdaq
Aandelen
US9256022032
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 6,94 mln. 6,45 mln. | Omzet 2023 | 8,01 mln. 7,43 mln. | Marktkapitalisatie | 5,25 mln. 4,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -21 mln. -19,5 mln. | Nettowinst (verlies) 2023 | -5 mln. -4,64 mln. | EV/omzet 2022 | -0,59 x |
Nettoliquiditeiten 2022 | 8,63 mln. 8,01 mln. | Nettoliquiditeiten 2023 | 10,87 mln. 10,09 mln. | EV/omzet 2023 | -0,7 x |
K/w-verhouding 2022 |
-0,2
x | K/w-verhouding 2023 |
-0,83
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,4% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01-12-20 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-16 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 01-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 01-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |